Form 4: MAIA Biotechnology Director Steven Chaouki Acquires Shares and Warrants

Director Steven M. Chaouki purchased 22,133 shares of common stock and warrants of MAIA Biotechnology, Inc. on November 1, 2024.

Summary

• On November 1, 2024, Steven M. Chaouki, a director of MAIA Biotechnology, Inc., acquired 22,133 shares of common stock at a price of $2.51 per share.
• The purchase was made pursuant to a Securities Purchase Agreement and the shares were issued under the Issuer's 2021 Equity Incentive Plan.
• Chaouki also acquired warrants to purchase 22,133 shares of common stock at an exercise price of $2.259 per share.
• These warrants, deemed options, were also purchased under a Securities Purchase Agreement and issued under the Issuer's 2021 Equity Incentive Plan.
• The options are exercisable beginning on May 1, 2025, and expire on May 1, 2030.
• Following the transaction, Chaouki directly owns 111,024 shares of MAIA Biotechnology, Inc. common stock and 22,133 warrants.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. Insider buying can be a positive signal, but it's a single transaction and doesn't guarantee future success.

Positives

• A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Insider transactions are closely monitored by investors as they can provide insights into a company's prospects, although they don't always predict future performance.

Stakeholder Impact

• The purchase could positively influence shareholder sentiment.

Key Dates